組織蛋白酶L(CTSL)重組蛋白
Recombinant Cathepsin L (CTSL)
CTSL1; CATL; CTS-L; MEP; Cathepsin L1; Major excreted protein
- 編號RPA306Hu01
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位溶酶體
- 預測分子量20.3kDa
- 實際分子量21kDa(差異分析請參閱說明書)
- 片段與標簽Ala114~Thr288 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 97%
- 等電點4.8
- 應用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1085 ¥ 2712¥ 5424¥ 16272¥ 40680
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
序列

用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產生。保質期內,在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關產品
編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
RPA306Hu01 | 組織蛋白酶L(CTSL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA306Hu01 | 組織蛋白酶L(CTSL)多克隆抗體 | WB; ICC/IF |
LAA306Hu71 | 組織蛋白酶L(CTSL)多克隆抗體(生物素標記) | WB |
MAA306Hu22 | 組織蛋白酶L(CTSL)單克隆抗體 | WB; IHC; ICC; IP. |
SEA306Hu | 組織蛋白酶L(CTSL)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA306Hu | 組織蛋白酶L(CTSL)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Hypertension | Identification of Cathepsin L as a Potential Sex-Specific Biomarker for Renal Damage. [Ahajournals: source] |
The Journal of International Medical Research | Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease[Ingenta: art00021] |
Atherosclerosis.? | Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery[Pubmed:24534452] |
International Journal of Molecular Sciences | A New Analytical Method for Determination of Cathepsin L Based on the Surface Plasmon Resonance Imaging Biosensor[Pubmed: 31052424] |
EMBO Molecular Medicine | Immune‐mediated ECM depletion improves tumour perfusion and payload delivery[Pubmed: 31709774] |
Cardiovasc Res | Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size[34132807] |